Search Within

Hematology-Oncology Fellows

Formats
  1. Meeting Abstract (2134)
  2. Journal Article (1757)
  3. Review (262)
  4. Editorial (133)
  5. Research Letter (85)
  6. Correspondence (45)
  7. Book Section (31)
  8. Guidelines (25)
  9. Miscellaneous (14)
  10. Conference Paper (8)
Groups
  1. Department of Medicine (4175)
  2. Weinberg Fellows (2758)
  3. Hematologic Malignancies, Division of (2493)
  4. Solid Tumor Oncology Division (2424)
  5. Center for Hematologic Malignancies (1945)
  6. GSK Faculty (1879)

More Groups

People
  1. Sergio Giralt (433)
  2. Michael Scordo (389)
  3. Gunjan Shah (348)
  4. Miguel-Angel Perales (338)
  5. Sean Devlin (289)
  6. Marcel Van Den Brink (263)

More People

Years
  1. 2025 (346)
  2. 2024 (636)
  3. 2023 (600)
  4. 2022 (628)
  5. 2021 (503)
  6. 2020 (496)

More Years

Publications
  1. Blood (713)
  2. Journal of Clinical Oncology (685)
  3. Annals of Oncology (133)
  4. Clinical Cancer Research (131)
  5. Cancer Research (126)
  6. Biology of Blood and Marrow Transplantation (124)

More Publications

Publishers
  1. American Society of Hematology (806)
  2. American Society of Clinical Oncology (774)
  3. Elsevier Inc. (544)
  4. Nature Publishing Group (358)
  5. American Association for Cancer Research (352)
  6. Oxford University Press (211)

More Publishers

Results (4494)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase II basket study of MCLA-128, a bispecific antibody targeting the HER3 pathway, in NRG1 fusion-positive advanced solid tumours
    Meeting Abstract

    Schram, A. M.; Drilon, A.; Macarulla Mercade, T.; O'Reilly, E. M.; Rodon, J. A.; Wolpin, B. M.; Ou, S. H. I.; Kim, D. W.; Yang, J. C. H.; Lam, Y. C. J.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Phase I dose escalation of MSC-1, a humanized anti-LIF monoclonal antibody, in patients (pts) with advanced solid tumours: Updated results
    Meeting Abstract

    Borazanci, E.; Schram, A.; Brana, I.; Vieito Villar, M.; Garralda, E.; Spreafico, A.; Oliva, M.; Lakhani, N.; Wasserman, R.; Hoffman, K.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: Results from the IMMUNOTARGET registry
    Journal Article

    Mazieres, J.; Drilon, A.; Lusque, A.; Mhanna, L.; Cortto, A. B.; Mezquita, L.; Thai, A. A.; Mascaux, C.; Couraud, S.; Veillon, R.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Towards individualized therapy for metastatic renal cell carcinoma
    Review

    Kotecha, R. R.; Motzer, R. J.; Voss, M. H.
    Nature Reviews Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Familial kidney cancer: Implications of new syndromes and molecular insights
    Review

    Carlo, M. I.; Hakimi, A. A.; Stewart, G. D.; Bratslavsky, G.; Brugarolas, J.; Chen, Y. B.; Linehan, W. M.; Maher, E. R.; Merino, M. J.; Offit, K.; more...
    European Urology (2019)

    Fulltext@MSK | Save
  • Lessons learned from routine, targeted assessment of liquid biopsies for EGFR T790M resistance mutation in patients with EGFR mutant lung cancers
    Journal Article

    Mondaca, S.; Offin, M.; Borsu, L.; Myers, M.; Josyula, S.; Makhnin, A.; Shen, R.; Riely, G. J.; Rudin, C. M.; Ladanyi, M.; more...
    Acta Oncologica (2019)

    Fulltext@MSK | Save
  • Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression
    Journal Article

    Aguilar, E. J.; Ricciuti, B.; Gainor, J. F.; Kehl, K. L.; Kravets, S.; Dahlberg, S.; Nishino, M.; Sholl, L. M.; Adeni, A.; Subegdjo, S.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Paradigms for precision medicine in epichaperome cancer therapy
    Journal Article

    Pillarsetty, N.; Jhaveri, K.; Taldone, T.; Caldas-Lopes, E.; Punzalan, B.; Joshi, S.; Bolaender, A.; Uddin, M. M.; Rodina, A.; Yan, P.; more...
    Cancer Cell (2019)

    Fulltext@MSK | Save
  • FGFR1 amplification mediates endocrine resistance but retains TORC sensitivity in metastatic hormone receptor-positive (HR(+)) breast cancer
    Journal Article

    Drago, J. Z.; Formisano, L.; Juric, D.; Niemierko, A.; Servetto, A.; Wander, S. A.; Spring, L. M.; Vidula, N.; Younger, J.; Peppercorn, J.; more...
    Clinical Cancer Research (2019)

    Fulltext@MSK | Save
  • A view on drug resistance in cancer
    Review

    Vasan, N.; Baselga, J.; Hyman, D. M.
    Nature (2019)

    Fulltext@MSK | Save